Abstract

Carnitine palmitoyltransferase (CPT) catalyzes the transfer of long- and medium-chain fatty acids from cytoplasm into mitochondria, where oxidation of fatty acids takes place. Deficiency of CPT enzyme is associated with rare diseases of fatty acid metabolism. CPT is present in two subforms: CPT I at the outer mitochondrial membrane and carnitine palmitoyltransferase II (CPT II) inside the mitochondria. Deficiency of CPT II results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. There is a lethal neonatal form, a severe infantile hepato-cardio-muscular form, and a rather mild myopathic form characterized by exercise-induced myalgia, weakness, and myoglobinuria. Total CPT activity (CPT I + CPT II) in muscles of CPT II-deficient patients is generally normal. Nevertheless, in some patients, not detectable to reduced total activities are also reported. CPT II protein is also shown in normal concentration in patients with normal CPT enzymatic activity. However, residual CPT II shows abnormal inhibition sensitivity towards malonyl-CoA, Triton X-100 and fatty acid metabolites in patients. Genetic studies have identified a common p.Ser113Leu mutation in the muscle form along with around 100 different rare mutations. The biochemical consequences of these mutations have been controversial. Hypotheses include lack of enzymatically active protein, partial enzyme deficiency and abnormally regulated enzyme. The recombinant enzyme experiments that we recently conducted have shown that CPT II enzyme is extremely thermoliable and is abnormally inhibited by different emulsifiers and detergents such as malonyl-CoA, palmitoyl-CoA, palmitoylcarnitine, Tween 20 and Triton X-100. Here, we present a conceptual overview on CPT II deficiency based on our own findings and on results from other studies addressing clinical, biochemical, histological, immunohistological and genetic aspects, as well as recent advancements in diagnosis and therapeutic strategies in this disorder.

Highlights

  • Carnitine palmitoyltransferase (CPT) catalyzes the transfer of long- and medium-chain fatty acids from cytoplasm into mitochondria, where oxidation of fatty acids takes place

  • The myosin heavy chain (MHC)-slow staining immunoreactivity was expressed predominantly in type I fibres both in the muscles of carnitine palmitoyltransferase II (CPT II) deficient patients and of controls [59]

  • In patients with the muscle CPT II deficiency, a common p.Ser113Leu mutation is identified in about 70% of mutant alleles [29,31,32,40]

Read more

Summary

Long-Chain Fatty Acids

Long-chain fatty acids (lcFA) are important sources of energy, especially for the heart, liver and muscles. They are used as the preferred substrate in the myocardium at rest and during prolonged exercise in skeletal muscle [1]. Fatty acids serve as building blocks for membrane lipids and cellular signaling molecules [2,3,4,5]. Ketone bodies produced in the liver during the oxidation of long-chain fatty acids can replace glucose in the brain and ensure the maintenance of normal content of sugar in the blood. Oxidation of fatty acids takes place in mitochondria.

Long-Chain Fatty Acid Transport System
Muscle Form of CPT II Deficiency
Clinical Presentations
Biochemical Features
Pathobiochemical Characteristics
Immunohistochemistry
Molecular Genetic Aspects
Recombinant Enzyme Studies
Genotype-Phenotype Analysis
Manifesting Heterozygotes
10. Treatment
Findings
11. Conclusions and Summary
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call